Non-Current Liabilities
Total Liabilities
Neurocrine Biosciences Total Liabilities increased by 8.7% to $1.50B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 30.1%, from $1.15B to $1.50B. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows an upward trend with a 17.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
A rising trend may indicate aggressive expansion or liquidity pressure, while a declining trend suggests deleveraging and improved balance sheet health.
Detailed definition
This represents the aggregate sum of all current and non-current financial obligations owed by the company to external p...
Peer comparison
Used across all industries to assess the overall debt burden relative to equity and assets.
Metric ID:
total_liabilitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $677.20M | $671.30M | $698.50M | $753.40M | $582.30M | $598.80M | $660.90M | $675.30M | $760.10M | $846.10M | $1.02B | $1.09B | $795.80M | $816.10M | $1.13B | $1.15B | $1.20B | $1.26B | $1.38B | $1.50B |
| QoQ Change | — | -0.9% | +4.1% | +7.9% | -22.7% | +2.8% | +10.4% | +2.2% | +12.6% | +11.3% | +20.5% | +6.6% | -26.7% | +2.6% | +38.3% | +2.0% | +3.8% | +5.6% | +9.2% | +8.7% |
| YoY Change | — | — | — | — | -14.0% | -10.8% | -5.4% | -10.4% | +30.5% | +41.3% | +54.2% | +60.9% | +4.7% | -3.5% | +10.8% | +6.0% | +50.2% | +54.7% | +22.1% | +30.1% |
Range$582.30M – $1.50B
CAGR+18.2%
Avg YoY Growth+20.1%
Median YoY Growth+16.4%
Current Streak7 quarters growth
Total Liabilities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's total liabilities?
- Neurocrine Biosciences (NBIX) reported total liabilities of $1.50B in Q1 2026.
- How has Neurocrine Biosciences's total liabilities changed year-over-year?
- Neurocrine Biosciences's total liabilities increased by 30.1% year-over-year, from $1.15B to $1.50B.
- What is the long-term trend for Neurocrine Biosciences's total liabilities?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's total liabilities has grown at a 17.8% compound annual growth rate (CAGR), from $608.50M to $1.38B.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors and stakeholders.